Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called an ALK rearrangement, confirmed through detailed genetic testing of tumour tissue
- People whose ALK rearrangement was originally detected by an earlier type of test may still be considered, as long as enough tumour tissue is available for the more detailed genetic test (confirm with trial site)
- People who have already been treated with one of three specific medications — alectinib, brigatinib, or lorlatinib — for at least 28 days as their first treatment
- People who are reasonably well and able to carry out daily activities, as assessed by a standard medical scale (ECOG performance score of 0, 1, or 2)
- People who are 18 years of age or older at the time of their diagnosis
- People who have signed a consent form approved by the local ethics committee
Who may not be able to join:
- People whose lung cancer does not have the ALK rearrangement genetic change
- People who stopped their ALK treatment early because of side effects, if there was no sign on scans that their cancer had grown or spread at that time
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: GIAMPAOLO TORTORA, Prof., Fondazione Policlinico Universitario A Gemelli
Phone: 3480510228
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of patients with available NGS testing at diagnosis; Percentage of patients with available NGS re-testing after progession (either tissue or ctDNA) to first-line treatment with II-III generation ALK-Inhibitor
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.